Maximal use pharmacokinetics and safety study of SNA-120: A novel topical therapy for pruritus associated with psoriasis

        Introduction: Pruritus is a distressing, yet often underappreciated symptom of psoriasis (PSO), one of many dermatoses currently lacking safe and effective topical, nonsteroidal, chronic treatment options. Tropomyosin receptor kinase A (TrkA) is the high-affinity receptor for nerve growth factor (NGF), which is implicated in pruritus and the visible plaque. SNA-120 (pegcantratinib) is a first-in-class topical TrkA inhibitor designed using proprietary Topical by Design technology to achieve high local drug concentration in the skin, minimizing systemic exposure. A phase 1b pharmacokinetic (PK) study was conducted to evaluate systemic exposure and safety of SNA-120 under maximal use conditions.
        To read this article in full you will need to make a payment
        AAD Member Login
        AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features
        One-time access price info
        • For academic or personal research use, select 'Academic and Personal'
        • For corporate R&D use, select 'Corporate R&D Professionals'

        Purchase one-time access:

        Already a print subscriber? Claim online access
        Already an online subscriber? Sign in
        Institutional Access: Sign in to ScienceDirect